<DOC>
	<DOCNO>NCT01715818</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel group , multicenter study evaluate potential aleglitazar reduce cardiovascular risk patient stable cardiovascular disease glucose abnormality . Patients randomize 1:1 receive either aleglitazar 150 mcg orally daily match placebo .</brief_summary>
	<brief_title>A Study The Potential Aleglitazar Reduce Cardiovascular Risk Patients With Stable Cardiovascular Disease Glucose Abnormalities</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female patient establish evidence stable cardiovascular disease ( CVD ) define least one follow group criterion ( A B ) A . Age &gt; /= 40 year history prior CV event prior myocardial infarction prior ischemic stroke ( confirm brain imaging study ) , onset &gt; /= 3 month prior randomization stable Investigator 's judgment B . Age &gt; /= 55 year evidence CVD ( stable Investigator 's judgment ) , define least one following : Coronary disease , cerebrovascular disease peripheral arterial disease define protocol Patients glucose abnormality base one follow AB criterion : A . Established Type 2 diabetes mellitus ( T2D ) accord 2010 ADA criterion ; treatment may include diet alone , glucoselowering therapy except thiazolidinediones ( TDZs ) B . No fulfillment criterion A ) evidence glucose abnormality Optimal management CV risk factor include hypertension dyslipidemia inform best evidence clinical practice guideline Current treatment thiazolidinedione ( TDZ ) fibrate Prior intolerance TDZ fibrate Previous participation trial aleglitazar Other type diabetes Inadequate liver , hematologic renal function Symptomatic heart failure classify NYHA class IIIV Hospitalization primary diagnosis heart failure 12month period precede randomization Peripheral edema judgment Investigator believe severe cardiac origin History surgical coronary revascularization ( CABG ) less 5 year prior screen , except case subsequent myocardial infarction Currently schedule arterial revascularization procedure Systemic corticosteroid therapy &gt; 2 week within 3 month prior screen Diagnosed treated malignancy ( except treat basal cell skin cancer , situ carcinoma cervix , situ prostate cancer ) within past 5 year</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>